Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 29, 2008
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, animal health) and institutions in North America and Europe. Operations are conducted through two reportable segments: Healthcare Distribution and Technology.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Sales | $1,525.6 million | $1,310.1 million |
| Gross Profit | $451.2 million | $391.0 million |
| Gross Margin | 29.6% | 29.8% |
| Operating Income | $85.2 million | $73.7 million |
| Net Income | $52.3 million | $43.5 million |
| Diluted EPS | $0.57 | $0.48 |
| Cash from Operations | $13.3 million | ($33.9 million) |
| Total Debt | $458.6 million | $456.6 million |
| Working Capital | $983.8 million | $908.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16.4% year-over-year. This was driven by a 12.0% increase in local currency (3.0% organic, 9.0% from acquisitions) and a 4.4% favorable foreign currency impact.
- Segment Performance:
- International: Sales surged 45.5% due to significant acquisitions (26.6%) and foreign exchange (13.3%).
- Dental: Sales grew 8.7%, driven by volume and acquisitions.
- Medical: Sales declined 3.7% due to a reduction in lower-margin pharmaceutical products; excluding these, internal growth was 4.5%.
- Technology: Sales increased 36.5%, driven by electronic and financial services growth.
- Profitability: Operating income rose 15.6% to $85.2 million. Gross margins contracted slightly (29.6% vs 29.8%) due to product mix changes, particularly in the Healthcare Distribution segment.
- Cash Flow: Operating cash flow improved significantly to a positive $13.3 million from a negative $33.9 million in the prior year, primarily due to reduced working capital outflows and higher net income.
Outlook, Risks, and Unusual Items
- Auction-Rate Securities (ARS) Liquidity Risk: The company holds approximately $36.0 million in ARS (student loans and municipal bonds). Since mid-February 2008, auctions have failed to settle, creating a liquidity constraint. Management does not currently believe these assets are impaired but notes that continued auction failures could necessitate an impairment charge.
- Capital Allocation: The company expects to invest $37.0 million to $42.0 million in capital projects for the remainder of the fiscal year. No common stock repurchases were made in Q1 2008, though $140.5 million remains available under the repurchase program.
- Debt Structure: The company has $240.0 million in convertible debt (3.0% fixed rate, due 2034) and $190.0 million in senior notes (variable rate, weighted average 7.9%). A $300.0 million revolving credit facility is available with no borrowings outstanding as of March 29, 2008.
- Internal Controls: Material changes in internal controls occurred due to the implementation of a new ERP system for the Italian Dental business and a Treasury Management system for the North American corporate office.
Investor Verification Checklist
- ARS Exposure: Verify the current status of the $36.0 million auction-rate securities portfolio and any potential impairment risks given the ongoing market freeze.
- Medical Segment Mix: Confirm the long-term impact of the reduction in lower-margin pharmaceutical sales on the Medical segment's profitability.
- Acquisition Integration: Assess the integration progress of recent acquisitions, which contributed significantly to the 9.0% organic growth in local currency sales.
- Working Capital Trends: Monitor accounts receivable days sales outstanding (increased to 42.2 days) and inventory levels to ensure cash flow stability.
- Convertible Debt: Review the terms of the $240 million convertible debt, specifically the cash settlement requirements upon conversion.